JP Morgan Chase’s Indaptus Therapeutics INDP Stock Holding History

JP Morgan Chase’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$9	–	7366
2025 Q1	$9	Hold	1	–	–	﹤0.01%	7192
2024 Q4	$16	Hold	1	–	–	﹤0.01%	7290
2024 Q3	$24	Hold	1	–	–	﹤0.01%	7232
2024 Q2	$32	Hold	1	–	–	﹤0.01%	7102
2024 Q1	$31	Buy	+1	New	+$53	﹤0.01%	7112
2023 Q4	–	Hold	0	–	–	–	7379
2023 Q3	–	Hold	0	–	–	–	7177
2019 Q3	–	Sell	-13	Closed	-$125K	–	5840
2019 Q2	$125K	Buy	+13	New	+$164K	﹤0.01%	4848
2018 Q2	–	Sell	-10	Closed	-$138K	–	5604
2018 Q1	$138K	Buy	+10	New	+$142K	﹤0.01%	4493

Other funds holding INDP

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase's INDP Position: Q2 2025 in Review

JP Morgan Chase sold out of Indaptus Therapeutics (INDP) in Q2 2025, closing a stake of 1 share — an estimated $9 sold.

JP Morgan Chase first reported a position in INDP in Q1 2018 and held it in 7 quarters. The position peaked at $138K in Q1 2018. 5 funds tracked by Wall St. Rank hold INDP as of Q2 2025.

JP Morgan Chase reported no remaining Indaptus Therapeutics position as of Q2 2025 after selling out during the quarter.
JP Morgan Chase sold 1 Indaptus Therapeutics share in Q2 2025, an estimated $9.
JP Morgan Chase first reported a position in Indaptus Therapeutics in Q1 2018 and held it in 7 quarters.
JP Morgan Chase's Indaptus Therapeutics position peaked at $138K in Q1 2018.
5 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.